REMODULIN Drug Patent Profile
✉ Email this page to a colleague
When do Remodulin patents expire, and what generic alternatives are available?
Remodulin is a drug marketed by United Therap and is included in two NDAs. There are five patents protecting this drug and two Paragraph IV challenges.
This drug has thirty-one patent family members in seven countries.
The generic ingredient in REMODULIN is treprostinil. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the treprostinil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Remodulin
A generic version of REMODULIN was approved as treprostinil by SANDOZ on November 30th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for REMODULIN?
- What are the global sales for REMODULIN?
- What is Average Wholesale Price for REMODULIN?
Summary for REMODULIN
| International Patents: | 31 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Clinical Trials: | 30 |
| Patent Applications: | 2,494 |
| Drug Prices: | Drug price information for REMODULIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for REMODULIN |
| What excipients (inactive ingredients) are in REMODULIN? | REMODULIN excipients list |
| DailyMed Link: | REMODULIN at DailyMed |
Recent Clinical Trials for REMODULIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Lung Biotechnology PBC | Phase 4 |
| Rhode Island Hospital | Phase 1/Phase 2 |
| University of Rhode Island | Phase 1/Phase 2 |
Pharmacology for REMODULIN
| Drug Class | Prostacycline Vasodilator |
| Physiological Effect | Vasodilation |
Paragraph IV (Patent) Challenges for REMODULIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| REMODULIN | Injection | treprostinil | 1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial | 021272 | 1 | 2012-12-07 |
| REMODULIN | Injection | treprostinil | 10 mg/mL, 20 mL vial | 021272 | 1 | 2011-12-02 |
US Patents and Regulatory Information for REMODULIN
REMODULIN is protected by five US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Therap | REMODULIN | treprostinil | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 208276-001 | Jul 30, 2018 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| United Therap | REMODULIN | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021272-004 | May 21, 2002 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| United Therap | REMODULIN | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021272-003 | May 21, 2002 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for REMODULIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| United Therap | REMODULIN | treprostinil | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 208276-001 | Jul 30, 2018 | ⤷ Start Trial | ⤷ Start Trial |
| United Therap | REMODULIN | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021272-002 | May 21, 2002 | ⤷ Start Trial | ⤷ Start Trial |
| United Therap | REMODULIN | treprostinil | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 208276-004 | Jul 30, 2018 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for REMODULIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| SciPharm Sàrl | Trepulmix | treprostinil | EMEA/H/C/005207Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity. | Authorised | no | no | yes | 2020-04-03 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for REMODULIN
See the table below for patents covering REMODULIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2630407 | ⤷ Start Trial | |
| South Korea | 20100074169 | BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGANIST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME | ⤷ Start Trial |
| Spain | 2045437 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch